BREAKINGON
eli lilly search result
EchoStar Soars After AT&T's $23 Billion License Deal as Markets Rally

EchoStar Soars After AT&T's $23 Billion License Deal as Markets Rally

BUSINESS - 8/26/2025

In a day marked by significant market movements, EchoStar's stock skyrocketed following AT&T's $23 billion purchase of wireless licenses. Eli Lilly also saw gains with promising diabetes drug results, while Nvidia's upcoming report looms large.

Eli Lilly's Obesity Pill: A Potential Game-Changer in Weight Loss?

Eli Lilly's Obesity Pill: A Potential Game-Changer in Weight Loss?

HEALTH - 8/24/2025

Eli Lilly's new obesity pill, orforglipron, faces tough competition but could disrupt the weight loss market. Despite underwhelming trial results, analysts see potential for success due to manufacturing advantages and pricing strategies.

Eli Lilly's Mounjaro Price Surge: What You Need to Know

Eli Lilly's Mounjaro Price Surge: What You Need to Know

HEALTH - 8/14/2025

Eli Lilly announces a dramatic price increase for its diabetes medication Mounjaro in the UK, raising the monthly cost from £122 to £330. This change affects private buyers but not NHS prescriptions. Learn more about the implications!

Novo Nordisk's CEO Steps Down Amid Market Challenges as Rival Sales Surge

Novo Nordisk's CEO Steps Down Amid Market Challenges as Rival Sales Surge

BUSINESS - 5/16/2025

In a surprising move, Novo Nordisk CEO Lars Fruergaard Jorgensen steps down as the company faces significant market challenges and competition from Eli Lilly's Zepbound. With share prices plummeting, the board seeks new leadership to navigate the turbulent landscape.

Pfizer Halts Development of Obesity Pill Amid Safety Concerns

Pfizer Halts Development of Obesity Pill Amid Safety Concerns

HEALTH - 4/14/2025

Pfizer Inc. has decided to stop the development of its obesity pill, danuglipron, after safety concerns emerged from a clinical trial. This move comes as competition heats up with Novo Nordisk and Eli Lilly's successful weight-loss treatments.

Eli Lilly's Orforglipron: The Game-Changer in Weight Loss Treatment

Eli Lilly's Orforglipron: The Game-Changer in Weight Loss Treatment

HEALTH - 3/24/2025

Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.

Eli Lilly Announces $27 Billion Investment in US Manufacturing Facilities

Eli Lilly Announces $27 Billion Investment in US Manufacturing Facilities

BUSINESS - 2/27/2025

Eli Lilly to invest $27 billion in building new US manufacturing plants amid challenges from drug import duties. The move aligns with Trump's push for American manufacturing revitalization.

Eli Lilly to Invest $50 Billion in US Manufacturing Expansion

Eli Lilly to Invest $50 Billion in US Manufacturing Expansion

BUSINESS - 2/26/2025

Discover how Eli Lilly's $50 billion investment in US manufacturing will create high-wage jobs, advance pharmaceutical innovation, and boost economic growth.

Eli Lilly Launches Cheaper Doses of Weight Loss Drug Zepbound for Uninsured Patients

Eli Lilly Launches Cheaper Doses of Weight Loss Drug Zepbound for Uninsured Patients

HEALTH - 2/25/2025

Eli Lilly introduces discounted higher doses of the weight loss drug Zepbound in a move to make the treatment more accessible to uninsured patients and address the growing demand for obesity treatments.

Can Ozempic Help Reduce Alcohol Consumption? New Study Reveals Surprising Findings

Can Ozempic Help Reduce Alcohol Consumption? New Study Reveals Surprising Findings

HEALTH - 2/13/2025

Discover how a new study suggests that Ozempic, a drug commonly used for diabetes and weight loss, may also help reduce alcohol consumption and cravings in individuals with alcohol-use disorder.

Breakingon.com is an independent news platform that delivers the latest news, trends, and analyses quickly and objectively. We gather and present the most important developments from around the world and local sources with accuracy and reliability. Our goal is to provide our readers with factual, unbiased, and comprehensive news content, making information easily accessible. Stay informed with us!
© Copyright 2025 BreakingOn. All rights reserved.